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Previous studies have shown that the human eosinophil is a  major effector cell in 
the complement-independent, antibody-dependent killing of the invasive larval stage 
(schistosomulum) of Schistosoma mansoni in vitro (1, 2). Early studies were carried out 
with eosinophils from normal, noneosinophilic individuals. However, helminth infec- 
tions,  including schistosomiasis,  are consistently associated with  increased  levels of 
eosinophils in the blood. Consequently, a formal comparison of the killing capacity of 
eosinophils from noneosinophilic and from moderately eosinophilic, helminth-infected 
patients  was  made,  which  showed  that  eosinophils  from  moderately eosinophilic 
individuals were markedly more active in killing schistosomula than were cells from 
noneosinophilic individuals (3). This suggested that eosinophilia may involve not only 
an  increased number of eosinophils in  the blood, but  also an  increased  functional 
activity of the individual ceils. 
Since previous work had suggested that eosinophila is a thymus-dependent phenom- 
enon  (4,  5), possibly attributable to soluble mediators (6,  7), the present study was 
undertaken in an attempt to relate eosinophilia to enhanced eosinophil function, by 
testing the hypothesis that  mononuclear ceils from eosinophilic individuals,  whose 
own eosinophils show an increased killing capacity, might produce an activity that 
could  stimulate  normal  eosinophils  and  increase their cytotoxic potential.  A  brief 
description of our preliminary findings has previously been published (8). 
Materials and Methods 
Media and Reagents.  The following  media and reagents .were used  in these  experiments: 
MEM: I Eagle's  Minimal Essential  Medium (Flow Laboratories), containing 20 mM Hepes, 
100 U/ml penicillin,  100/tg/ml streptomycin, and 30 mg/1 DNase, pH 7.3. MEM/FCS: MEM 
supplemented with  10% fetal calf serum (FCS)  (Seralab),  heat-inactivated at 56°C for 1 h. 
PBS:  Phosphate-buffered saline, pH 7.3. PBS azide was supplemented with 0.1% sodium azide. 
Con A: Concanavalin A (Type IV, Sigma Chemical Co.) prepared as a stock solution at 1 mg/ 
ml in MEM and used at  10/tg/ml in either MEM or MEM/FCS. Emetine dihydrochloride 
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(Boehringer) prepared as a stock solution of i00 mM in distilled water and used at I X IO-4M 
in MEM/FCS. 
Schistosoma mansoni Life  Cycle and Preparation of Schistosomula.  A  Puerto Rican isolate of S. 
mansoni is routinely maintained in this laboratory by passage through laboratory-bred Biom- 
phalaria glabrata snails and BALB/c mice. Schistosomula were prepared by allowing infective 
cercariae to penetrate an isolated preparation of rat skin in vitro, according to the method of 
Clegg and Smithers (9). 
Sera.  Sera taken either from baboons chronically infected with S. mansoni or pooled from 
patients with S. mansoni infection were used as a source of antibody. Normal human sera were 
prepared from noninfected, noneosinophilic laboratory workers.  Sera were heat-activated at 
56°C for 1 h and were stored in frozen aliquots at -20°C. 
Preparation of Cells.  Mononuclear cells,  neutrophils, and eosinophils were  purified from 
heparinized human peripheral  blood  by  dextran  sedimentation and centrifugation of the 
resulting leukocyte-rich supernatant through slightly hypertonic, discontinuous metrizamide 
gradients, as described by Vadas et al. (10). Preparations containing  >90% mononuclear cells, 
neutrophils, or eosinophils were routinely obtained from the  18%, 22%, and 24%  interfaces 
respectively. Such cells were washed three times in MEM/FCS, counted, and resuspended at 
an appropriate concentration. Cells in the original peripheral blood and in the purified fractions 
were counted with the aid of a Coulter counter (Coulter Electronics Limited), and differential 
counts were carried out on Giemsa-stained blood smears or cytocentrifuge preparations. Cell 
viability was checked by Trypan Blue exclusion. 
In some experiments, mononuclear  cells were prepared by an alternative method. Peripheral 
blood from moderately eosinophilic individuals was defibrinated, diluted 1:1 vol/vol in MEM 
(without FCS), and layered over an equal volume of Lymphoprep (Nyegaard). After centrifu- 
gation for 40 min at 400 g, the overlaying serum was removed and the interface cells were 
collected, washed four times in MEM, counted, and resuspended at an appropriate concentra- 
tion. 
Preparation of mononuclear Cell Supernatants (MCS).  For routine preparation of MCS, metri- 
zamide-fraetionated mononuclear cells from normal or moderately eosinophilic donors (100- 
1,900 eosinophils/mm  3) were cultured in MEM/FCS in a humidified atmosphere of 5% CO2/ 
95% air, at 37°C, at a concentration  of 5-10 x  106 cells/ml, in round-bottomed tubes containing 
1-2-ml volumes. Cell-free supernatants were collected after varying periods of time, usually 24 
h, and were filtered and stored at -20°C. In some experiments, Lymphoprep-fractionated cells 
were cultured under similar conditions in serum-containing  or serum-free media. 
Adherent mononuclear cell supernatants (MCS) were prepared as follows. Aliquots of 1 X 
10  ~ mononuclear cells were incubated in flat-bottomed plastic culture wells (Linbro multiwell 
plate, Flow Laboratories)  in  1 ml MEM/FCS for  1 h  at 37°C. Unattached cells were then 
removed and replated in another well for  1 h, whilst the remaining adherent cells were rinsed 
several times with MEM/FCS and reincuhated for a further 2 h. After this period the adherent 
cells were washed vigorously with several changes of MEM/FCS, and were finally cultured for 
24 h  at 37°C, to provide the "adherent" cell supernatant. The "nonadherent" supernatants 
were obtained by serially replating the original unattached cells three times, to remove any 
remaining adherent cells, and by culturing the resulting nonadherent cells for 24 h as above. 
Treatment of Mononuclear Cells with an Antilymphocyte Monoclonal Antibody.  The rat monoclonal 
antilymphocyte antibody, CAMPATH 1, prepared from ascitic fluid by ammonium sulphate 
precipitation and reconstituted to 5 mg/ml in PBS, was kindly provided by Dr. H. Waldmann 
(Department of Pathology, University  of Cambridge). This antibody kills >99% of all peripheral 
blood lymphocytes in the presence of human complement, but spares monocytes (Hale, G., S. 
Bright, G. Chumbley, T. Hoang, D.  Metcalf, A.  Munro, and H. Waldmann, submitted for 
publication). 
Aliquots of 5  X  106  mononuclear cells  from  a  moderately eosinophilic individual were 
incubated in 1 ml of either MEM/FCS or the monoclonal antibody (diluted 1/50 in MEM/ 
FCS) for 30 rain at 37°C. The cells were washed once, and resuspended in 0.5 ml of MEM/ 
FCS or of fresh autologous serum (diluted 1/4 in MEM/FCS) as a source of complement, and 
reincubated for  a  further 45  rain at  37°C.  The  cells  were  then  washed  three  times,  and 
resuspended in 1 ml of MEM/FCS. Cell viability and total cell  numbers were determined, 1830  ENHANCEMENT OF HUMAN  EOSINOPHIL  CYTOTOXICITY 
before incubation for a further 24 h to obtain the MCS. 
Fractionation of Mononudear Cell Supernatants. 
(a)  ULTRAFILTaATION: Mononuclear cell supernatants derived from an eosinophilic indi- 
vidual were pooled and passed through a series of Amicon diaflo membranes (Amicon Corp.) 
at a pressure of either 50 or 70 lb/in  2 at room temperature. MEM was used to flush the filters 
and reconstitute the residue. 
(b)  SEPI-IADEX  CHROMATOGRAPHY:  A G-200 Sephadex column, 1.5  ×  80 cm, prepared in 
PBS azide at 4°C, was calibrated with a mixture of protein standards (molecular weight range 
21 to 210 ×  t0s), a trace amount of [a~I] tyrosine and dextran blue 2000. The column was then 
equilibrated in sterile MEM to remove the azide, and a pool of MCS from a single eosinophilic 
individual, previously concentrated 10-fold by ultrafiltration through a UM20E diaflo mem- 
brane, was applied• The fractions were collected and stored at -20°C. To test  the enhancing 
capacity of the various fractions, the tubes were thawed and aliquots of each fraction were 
pooled in series of four, filtered, and then preincubated with eosinophils in the usual manner 
(below). 
Cytotoxicity Assay.  Aliquots of 50 #1 of eosinophils were mixed and preincubated for 1 h at 
room temperature with 50 #1 of mononuclear cell supernatant, at various dilutions, in 7-mm 
×  38-ram  round-bottomed tubes  (LP2,  Luckham).  Aliquots of 50  #1  of antiserum, at  an 
appropriate dilution, and of sehistosomula, usually at  2,000/ml, were subsequently added, 
mixed, and incubated for a  further 40-50 h  at  37°C in humidified plastic boxes.  Control 
preparations contained equivalent volumes of medium instead of eosinophils and/or antibody. 
At the end of the incubation period, schistosomulum viability was scored microscopically by 
toluidine blue exclusion (10). 
Cell Protein Synthesis• 
(a)  [35S]METHIONINE  UPTAKE  IN  THE  PRESENCE  OR ABSENCE  OF  EMETINE:  Peripheral blood 
mononuclear cells were washed twice in methionine-free MEM, counted and maintained in 
methionine-free medium for a further 15 min at 37°C. The cells were adjusted to 1 ×  106/ml, 
and 2-ml aliquots were dispensed into 15-ml conical tubes (Falcon Labware) with or without 
1 ×  10-4M emetine dihydrochloride. Immediately thereafter, 40 pCi [35S]methionine was added 
to both emetine-treated and control tubes (0 h). Triplicate samples of 100 pl were taken from 
both tubes and were precipitated with 2 ml of 10% iced trichloracetic acid (TCA) in tubes 
containing 25 #l of 1% bovine serum albumin as a carrier protein. Samples were taken at 0 h 
and 1 h, whilst the cells remained incubating at 37°C. After 1 h, the cells were washed three 
times in methionine-free  medium, resuspended in 1 ml and counted. More [35S]methionine was 
added to both tubes and additional samples were collected after a further 1, 3, and 5 h. The 
resultant TCA precipitates were filtered onto Whatman GF/C filters, dried overnight at 37°C, 
solubilized, and counted in a liquid scintillation counter (LKB). 
(b)  MCS PRODUCTXON ~N THE PRESENCE OR ABSENCE OF EMETINE:  Mononuclear cells from a 
moderately eosinophilic individual were incubated at 5 x  106/ml, for 1 h or 3 h, at 37°C, with 
1 X 10-4M emetine dihydrochloride. The cells were then washed three times and recultured for 
a further 3 or 5 h. Control preparations without emetine were treated identically. Viability of 
•  6  l  cells  at  all stages  was >89%.  The final cell  concentrattons ranged from  3 to 3.3  ×  10/m. 
Supernatants were collected after the 3 or 5 h culture periods, filtered, and stored at -20°C 
before testing for enhancing activity. 
Analysis of Data.  Groups of replicate samples in the cytotoxicity and other assays  were 
compared by the Student's t test. 
Results 
Eosinophils from Eosinophilic Individuals Demonstrate Increased Killing Activity.  Previous 
studies  have  shown  a  significant correlation  between  peripheral  blood  eosinophil 
counts and the schistosomulum-killing  activity of individual eosinophils (3). Eosino- 
phils from moderately eosinophilic and normal individuals were then compared in 
more  detail  for  their  capacity  to  kill  schistosomula  in  the  presence  of  varying 
concentrations of antischistosomular antibody or at varying effector to target ratios 
(Fig.  1).  Eosinophils  from  some  eosinophilic  individuals demonstrated  markedly 50- 
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Fro.  1.  Eosinophils from eosinophilic individuals demonstrate an increased killing capacity. Schis- 
tosomula were incubated  for 40 h with eosinophils from either an eosinophilic individual  (0) (1,022 
Eos/mm  a, 89% pure) or a normal individual  (O) (168 Eos/mm  a, 91% pure), at varying effector to 
target (E:T) ratios in the presence of varying concentrations of immune human serum (Ab). Each 
point represents the mean +  1 SD of triplicate tubes. 
increased  levels of killing at  all antibody concentrations  tested,  at a  fixed effector to 
target ratio, and at all ratios tested, at a  fixed antibody dilution. 
Enhancement  of  Eosinophil-mediated  Killing  by  Mononuclear  Cell  Supernatants 
(MCS).  Supernatants  of mononuclear  cell  cultures  from  eosinophilic  individuals, 
whose own eosinophils  showed high  killing activity, significantly enhanced  the anti- 
body-dependent,  complement-independent  capacity of eosinophils to kill schistosom- 
ula  in vitro.  Such  supernatants  were active at  dilutions  of up  to  1/400.  1 out  of 60 
experiments  in  which  such  enhancement  was  demonstrated  is  shown  in  Fig.  2. 
Immune human or immune baboon serum could be used equally effectively. In some 
experiments a  slight enhancement  of antibody-independent  killing was observed, but 
this  was  a  less  pronounced  and  less consistent  finding.  The supernatants,  although 
present throughout  the assay, were not directly toxic to the schistosomula. 
Comparison of the Effects of MCS from Normal and Eosinophilic Individuals.  Undiluted 
supernatants  from mononuclear cell cultures of both eosinophilie and normal individ- 
uals  demonstrated  an ability to enhance  eosinophil-mediated  killing  (Table I, Expt. 
1), but the capacity of supernatants from normal individuals to enhance killing, when 
detectable, tended to titrate out more acutely (Table I, Expts. 3, 4, and 5). Routinely, 
the MCS from four eosinophilic and four noneosinophilic  individuals have been used, 
but  similar results have been obtained  with supernatants  prepared  from  16 Kenyan 
patients  (data not shown).  Eosinophils both from normal individuals  (Table I, Expts. 
4-6) and also from eosinophilic individuals  (Table I, Expts.  1-3), could be stimulated 
by these supernatants.  Eosinophils from eosinophilic individuals could also be further 1832  ENHANCEMENT  OF  HUMAN  EOSINOPHIL  CYTOTOXICITY 
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FIO.  2.  Enhancement of eosinophil-mediated  killing of schistosomula by  the  mononuclear cell 
supernatant of an eosinophilic individual. Schistosomula were incubated for 40 h in the presence or 
absence of eosinophils (Eos) and immune baboon serum (Ab) at  1/480. The eosinophils had been 
preincubated for 1 h  either in control medium or in 24 h  MCS (at a  final dilution of 1/4 or  1/40) 
derived  from the mononuclear cells of an eosinophilic individual, and were  added to the assay, 
without washing, at an effector to target ratio of 2,000:1, Each point represents the mean =1= 1 SD 
of three replicate  tubes. Clear bar,  medium; speckled bar,  supernatant  1/40;  cross-hatched bar, 
supernatant 1/4. 
stimulated by MCS prepared from the same individual (Table I, Expts. 1-3). 
MCS  Do Not Affect  Neutrophil-mediated  Killing.  Eosinophils and  neutrophils  were 
prepared under identical conditions from the same peripheral blood. When tested in 
the cytotoxicity assay, eosinophils at an effector to target ratio of 1,000:1  showed a 
low level of killing in the unstimulated controls (Fig. 3), but demonstrated a marked 
enhancement following preincubation for 1 h in MCS prepared from an eosinophilic 
individual.  In  contrast,  neutrophils  at  a  ratio of 4,000:1  showed  no  demonstrable 
killing  in  the  unstimulated  controls, nor was  any enhancement  of any  previously 
undetectable killing evident after similar preincubation in MCS. 
Stimulation  of Eosinophils  by  MCS  is  Not  Reversed by  Washing.  Experiments  were 
undertaken to test whether the continued presence of MCS was required for enhanced 
killing. Eosinophils were preincubated for 24 h in control medium or in MCS from an 
eosinophilic  individual.  Thereafter, they  were  washed  three  times  to  remove  the 
stimulating activity, before addition to the usual cytotoxicity assay in the presence or 
absence  of further  MCS.  Additional  preparations  were  tested  without  washing. 
Eosinophils  that  had  been  previously  preincubated  in  MCS,  then  washed  and 
resuspended  without  further  stimulation,  still  showed  a  significantly  (P  <  0.05) 
enhanced killing activity during the subsequent 40-h assay (59 +  4%), in comparison T
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FIO.  3.  Neutrophil-mediated killing of schistosomula  is not enhanced by the mononuclear cell 
supernatant  (MCS)  of an eosinophilic  individual. Schistosomula were incubated  for 40 h  in  the 
presence  of neutrophils (NEUTROS), eosinophils  (EO~), or medium (MED), and immune human 
serum at 1/20. The cells had been preincubated for 1 h either in medium (MED) or in supernatant 
(MCS) from a 24-h culture of mononuclear cells from an eosinophilic  individual, and were added to 
the  assay  without  washing.  Neutrophils  were  tested  at  an  effector to  target  ratio  of 4,000:1; 
eosinophils  were tested at 1,000:1. Each point represents  the mean +  1 SD of three replicate tubes. 
with  unstimulated  preparations  preincubated  in  medium  alone  (42  :!= 9%).  Control 
cells preincubated  in medium,  and washed in the same way, could still be stimulated 
when  MCS  was  added  during  the  cytotoxicity  assay  (69  +  5%),  whereas  the  pre- 
stimulated  and washed eosinophils could not be further stimulated  (60 +  11%). 
Properties of the Stimulating Activity  im MCS.  When  24-h  MCS  from an eosinophilic 
individual were heated at 56°C, 80°C, or  100°C for 30 min, the capacity to enhance 
killing  was  not  significantly  affected  by  heating  at  56°C  (Table  II).  Above  this 
temperature,  a  progressive  loss  was  noted,  although  some  activity  still  remained 
following heating at  100°C. 
In addition,  it was  found  that  the activity was retained  by ultrafiltration  through VEITH  AND BUTTERWORTH  1835 
TABLE II 
Heat Stability of MCS Activity 
% Dead schistosomula* 
Dilution of MCS: 
1/I  I/3.2  1/10  1/32  1/100 
Eos preincubated in MCS: 
Unheated  75 3= 5*  60 3= 1  33 3= 10  11 + 4  8 + 3 
Heated 56°C, 30 rain  78 3= 1  53:1:3  25 ± 3  18 ±  7  12 ± 5 
80°C, 30 min  65:1:9  37 ± 2  20 + 4  15 ± 3  14 3= 6 
100°C, 30 min  62 3= 8  24 3= 6  20 3= 1  12 3= 5  12 ± 5 
Medium control  6 +  3  .... 
Antibody only  3 ± 3 
Unheated MCS only  2 + 2 
* MCS from an eosinophilic individual were heated to either 56°C, 80°C, or 100°C for 30 min and were 
subsequently  tested  for enhancing  activity.  Eosinophils were preincubated for 1 h in MCS at various 
dilutions and were added, unwashed, to schistosomula with immune human serum (1/120) at an effector 
to target ratio of 500:1. 
* Mean 3= 1 SD, three replicate tubes. 
a  UM10  diaflo  membrane,  indicating a  molecular weight  of greater  than  10,000. 
Subsequent  sequential  ultrafiltration  through  a  series  of Amicon  filters  (UM20E, 
XM50,  XM100A)  showed  that  the  activity was  retained  at  least  up  to  a  nominal 
molecular weight cut-off of 100,000.  However, fractionation on G-200 demonstrated 
a  major peak of enhancing activity which, when compared to the molecular weight 
markers, gave an estimated molecular weight of 35,000-45,000  (Fig. 4). 
Production of Eosinophil-stirnulating  Activity by Mononuclear Cells.  When supernatants 
of mononuclear  cell cultures  were  harvested  after  various  intervals  and  tested  for 
enhancing activity, significant (P <  0.05) stimulatory capacity was detectable as early 
as  1 h  of culture (Table III). A  gradual increase in activity was evident up to 6  h  of 
culture, after which the activity reached a  plateau level. Mononuclear cells cultured 
for 24 h, washed three times and recultured for a further 24 h still produced significant 
(P <  0.01)  enhancing activity (T 24 +  24, Table III). 
In  early  experiments,  it  was  assumed  that  some  mitogenic  stimulant  might  be 
required for the production of enhancing activity. Initial MCS were therefore prepared 
in the presence or absence of 10 #g/ml concanavalin A  (Con A). At the end of the 
culture period, the supernatant  fluids were collected and the unstimulated superna- 
tants were reconstituted with  Con  A. When  these MCS  were  tested, no  differences 
were observed in the capacity of stimulated and reconstituted supernatants,  respec- 
tively, to  enhance  eosinophil-mediated killing  (data not  shown).  In  all subsequent 
experiments therefore,  no Con  A  was  added.  In separate experiments mononuclear 
cells  were  purified  by  defibrination  of  peripheral  blood  and  centrifugation  over 
Lymphoprep,  with  serum-free  medium  being  used  throughout  the  procedure.  The 
cells from the interface were then cultured with or without serum supplement. It was 
found that the production of significant enhancing activity was possible in the absence 
of serum, but  that such  MCS  required a  subsequent  addition of serum to minimize 
the loss of activity upon filtration (data not shown). 
To ascertain whether production of the stimulatory activity depended on protein 
synthesis,  mononuclear  cells  from  an  eosinophilic  individual were  cultured  in  the 1836  ENHANCEMENT  OF HUMAN EOSINOPHIL CYTOTOXICITY 
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FzG. 4.  Sephadex  G-200 fractionation  of the mononuclear  cell supernatant  of an eosinophilic 
individual. A column of Sephadex G-200 (1.5 X 80 era) was prepared in PBS azide, pH 7.3 at 4°C, 
and calibrated with molecular weight marker proteins. The column was then equilibrated in sterile 
MEM under identical conditions and a concentrated  (X 10) sample of MCS (<1% of bed volume) 
was applied and eluted by reverse flow at a rate of 3.8 ml/h. Fractions of 1.3 ml were collected, and 
aliquots  of these were pooled in series of four and tested for enhancing  activity in an antibody- 
dependent eosinophil-mediated  cytotoxicity assay (Materials and Methods). Each point represents 
the mean :1:1 SD of three replicate tubes. * These values differ significantly (P <  0.001) from the 
control (eosinophils preincubated in medium alone). 
presence or absence of emetine dihydroehloride. To  test  whether  emetine inhibited 
protein  synthesis  under  conditions  appropriate  for  the  production  of  MCS,  the 
incorporation of [~S]methionine into mononuclear cells was measured. There was no 
increase in [~S]methionine incorporation by emetine-treated cells between 0  h  and  1 
h  of culture (27,000 ±  11,000 to 22,000 ±  1,000 cpm). Similarly there was no increase 
in incorporation from  1 h  to 5  h,  following the removal of emetine  (8,000  ±  650  to 
7,000  ±  300 cpm).  In contrast, untreated control cells doubled their [35S]methionine 
counts between 0  h  and  1 h  (24,000  ±  12,000  to 42,000:1:9,000  epm) and showed a 
progressively increased incorporation after the cells were washed, between  1 h  and 5 
h  (25,000  +  3,000  to 47,000  ±  4,000  epm).  These data showed that  emetine, under 
these conditions, inhibited protein synthesis and that  it could be removed after  1 h 
without  allowing a  resurgence of protein synthesis within  the following 5-h culture 
period. 
Mononuclear  cells  from  an  eosinophilic  individual  were  then  cultured  in  the 
presence or absence ofemetine (1  X  10 -4 M)  for 1 or 3 h, washed, and reeultured for 
a  further  3  or  5  h,  and  the  resulting supernatants  were  tested  for  their enhancing 
potential (Table IV). MCS prepared from cells cultured without emetine significantly VEITH  AND BUTTERWORTH 
TABLE III 
Time Course of Production of Enhancing Activity 
1837 
% Dead schistosomula* 
Eos preincubated in: 
+Eos*  +Eos  +Medium 
+IHS  +NHS  +Medium 
Medium  8±3 ~  2+  1  1 ±  1 
MCS lh  15:t:31  2+ 1  2~- 1 
2h  21+31  1:t:2  0±0 
4h  41 +5 Rx  5"*" l I  1 +2 
6  h  53 :t: 9 n  10 +  4 |  0 
8h  52±3 u  8-1-6  0 
24 h  57 ± 41  25 ± 81  0 
24h+ 24h  28"1-81  4±3  2± 1 
* Schistosomula were incubated for 40 h in the presence or absence of eosinophils (Eos) and 
heat-inactivated immune human serum (IHS) or normal human serum (NHS) at 1/120. 
The eosinophils had been preincubated for 1 h either in control medium or in ~ dilutions 
of MCS harvested from mononuclear cells from an eosinophilic individual after L, 2, 4, 6, 
8, and 24 h of culture.  The mononuclear  cells which had been cultured for 24 h were 
washed three times, checked for viability, and recultured for a further 24 h (24 h + 24 h). 
The eosinophils were added to the cytotoxicity assay without washing. 
* Effector to target ratio was 1,200:1. 
§ Mean "4- 1 SD, replicate tubes. 
I Values differ from the medium controls at P < 0.05 or less. 
(P  <  0.005)  enhanced  eosinophil-mediated killing of schistosomula,  whereas  MCS 
prepared from cells preincubated with emetine for 1 or 3 h, and cultured for 3 or 5 h 
thereafter, demonstrated no enhancement. 
Nature  of the  Cell  Producing the  Eosinophil-stimulating  Activity.  When  mononuclear 
cells, eosinophils or neutrophils, purified from the peripheral blood of an eosinophilic 
individual, were cultured under identical conditions for 24 h, only the supernatant of 
the  mononuclear  cell  culture  demonstrated  significant  stimulation  of  eosinophil- 
mediated  killing  (8).  The  mononuclear  cell  population  consisted  of a  mixture  of 
monocytes and lymphocytes, usually contaminated with <5% neutrophils. In further 
experiments  populations  of predominantly  adherent  or  nonadherent  mononuclear 
cells were prepared. When supernatants  were harvested from these two populations 
and  tested  for enhancing  activity, there was  a  significant  (P <  0.001)  difference in 
their  ability to  stimulate  eosinophil-mediated killing  (Fig.  5).  The  MCS  prepared 
from the adherent population demonstrated significant (P <  0.001) enhancing activity, 
comparable to that produced by unfractionated cells. In contrast, the MCS from the 
nonadherent  population  showed  some  enhancement,  but  less  than  the  MCS  from 
unfractionated or from adherent cells. In a  further experiment, it was found that the 
adherent  population, which produced significant enhancing activity, was composed 
of cells 92% of which stained positively for nonspecific esterase (11). 
To test the possibility that an adherent T  lymphocyte was producing the activity, 
a  monoclonal  antilymphocyte antibody  and  complement  were  used  to  kill both  T 
and  B  lymphocytes  (Table  V).  When  mononuclear  cells were  treated  with  either 
medium, antibody, or complement only, there was no loss of cell viability and in each 
case  the  resulting  MCS  demonstrated  significant enhancing  activity. When  mono- 1838  ENHANCEMENT  OF  HUMAN  EOSINOPHIL CYTOTOXICITY 
TABL~  IV 
Emetine Inhibits the Production of Enhancing Activity by Mononuclear Cells 
% Dead schistosomula* 
Eos preincubated in  Culture pe- 
riod after  Experiment 1  Experiment 2 
MCS  from mononu- 
removal of 
clear  cells  incubatcd 
emetine  +Eos*  -Eos  +Eos  -Eos 
+IHS  -IHS  +IHS  -IHS 
Without emetine for: 
lh  3h  41±4  §**  1 ±0  8i  +3"*  10 
lh  5h  51+7"*  2±2  80+4"*  11±4 
3 h  3 h  48 ±  15"*  2  NT  NT 
3 h  5 h  52:1: 6**  1 ±  2  NT II  NT 
With emetine for: 
lh  3h  8±4  3±0  22±  1  13±4 
lh  5h  3:1:1  4±2  30±6  14±3 
3h  3h  5±  1  9±3  NT  NT 
3h  5h  5±3  3:t:  1  NT  NT 
Eos preincubated in  --  6 ±  5  4 ±  0  29 ±  2  9 ±  3 
medium 
* Sehistosomula were  incubated  for 40  h  in  the  presence or  absence of eosinophils  (Eos)  and  heat- 
inactivated  immune human serum  (IHS)  at  1/120.  The eosinophils had  been  preincubated  for  i  h 
either in medium or in the undiluted supernatants prepared from mononuclear cells of an eosinophilic 
individual.  The mononuclear cells  had been incubated  for  1 or 3 h  with emetine  (I  ×  10-4M),  and 
washed three times, and the supernatants were harvested after a  further 3 or 5 h. Control MCS were 
prepared from cells not treated with emetine. 
* Effector to target ratio was 1,600:1  (Expt.  1),  1,500:1  (Expt. 2). 
g Mean ±  1 SD, three replicate tubes. 
NT, not tested. 
** Values differ from control preparations containing Eos preincubated in medium alone at P <  0.05  or 
less. 
nuclear cells were treated with both antibody and complement, 76% of the cells were 
killed. The MCS derived from the remaining cells showed no loss of enhancing ability. 
Discussion 
The results presented here are consistent with the interpretation that a nonlympho- 
cytic, nonspecific esterase-containing, adherent mononuclear cell is responsible for the 
production of a relatively heat-stable activity, with an estimated molecular weight of 
35-45,000,  which  can  enhance  the  antibody-dependent,  and  to  some  extent  the 
antibody-independent killing of schistosomula by eosinophils. 
It has been known for some time that the functional properties of mature eosinophils 
can  be  altered  by  incubation  in  the  presence  of various  mediators.  For example, 
eosinophil stimulation promoter (ESP), a T cell mediator, stimulates the migration of 
eosinophils out of agarose droplets (12), and an ESP-like activity permits the eosino- 
phil-mediated  destruction  of schistosome  eggs  in  vitro  (13).  Likewise  eosinophil 
chemotactic factor of anaphylaxis  (ECF-A)  not  only is  selectively chemotactic for 
eosinophils, but also enhances the expression of human eosinophil receptors for Fc, 
C3b, and C4  (14,  15), and increases both eosinophil-mediated, antibody-dependent 
and eosinophil-mediated, complement-dependent killing of schistosomula in vitro (16, 
17). 
Since schistosomiasis is classically associated with eosinophilia, a  study has been VEITH AND BUTTERWORTH  1839 
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Fro. 5.  Adherent nature of the cell producing the enhancing activity. Schistosomula were incu- 
bated for 40 h in the presence or absence of eosinophils (2,000:1) and immune human serum at 1/ 
120. The eosinophils had been preincubated for 1 h either in medium or in one of the MCS shown 
above, and were added to the assay without washing. The MCS were made from mononuclear cells 
of an eosinophilic individual prepared by successive replating and washing to obtain adherent and 
non-adherent cell populations. Error bars represent 1 SD for three replicate tubes. 
previously undertaken  to compare the capacity of eosinophils from eosinophilic and 
normal individuals  to kill schistosomula in vitro (3). This study showed that eosino- 
phils from eosinophilic individuals demonstrate an increased killing activity, and may 
be in an "activated"  state  in vivo. In various systems, the induction of eosinophilia 
has  been  found  to be  a  T  lymphocyte-dependent  phenomenon  (4,  5)  that  may be 
attributable to the release of soluble mediators (6, 7). Murine lymphocytes can release 
colony-stimulating  factors  (E.CSF)  that  will  specifically  accelerate  the  growth  of 
eosinophil  colonies  in  bone  marrow  cultures  in  vitro  (18,  19).  In  addition,  CSF-a 
partially purified from human placenta-conditioned medium (HPCM)  (20), not only 
demonstrates  eosinophil colony-stimulating activity (21), but can also enhance anti- 
body-dependent eosinophil-mediated killing in vitro (22). 
In  the  present  study,  in  order  to  test  in  more  detail  the  relationship  between 
eosinophilia  and  eosinophil  activation,  we  asked  whether  mononuclear  cells  from 
eosinophilic  individuals  would produce mediators  that would affect the  function of 
mature  eosinophils.  When  mononuclear  ceils  from an  eosinophilic  individual  were 
cultured  with  or  without  Con  A,  and  the  resulting  supernatants  tested  for  their 
capacity to enhance eosinophil-mediated killing, a marked enhancement was noted in 
both  cases.  The production  of enhancing  activity was  independent  of mitogenic or 
antigenic stimulation,  and did not require serum in the culture medium. 1840  ENHANCEMENT  OF HUMAN EOSINOPHIL CYTOTOXICITY 
TABLE V 
Effect of MCS Prepared  from Cells Pretreated with an Antilymphocyte Monoclonal  Antibody and 
Complement 
Pretreatment of mononuclear cells*  Final cell 
viability* 
% Dead schistosomula  § 
+Eos  -Eos 
+Ab  -Ab 
Medium only  100  60 + 6  ~  0 + 0 
Antibody only  100  68 + 3  0 ± 0 
complement only  100  78 ± 6  0 ± 0 
Antibody + complement  24  62 ± 6  1 ±  1 
Controls: 
Unstimulated EOS. Preineubated in medium  18 ±  15  0 ± 0 
* Mononuclear  cells from an eosinophilic individual were incubated for 30 min at 37°C with or without 
antibody (monoelonal CAMPATH 1 at 1/50), washed, and subsequently incubated for 45 min at 37°C 
with or without complement  (fresh autologous serum at 1/4). 
*  Treated cells were washed three times and the viability  determined by Trypan Blue exclusion. Superna- 
tants were recovered after a further 24 h of culture. 
§ Schistosomula were incubated for 40 h in the presence or absence of eosinophils (EOS) and immune 
human serum (Ab) at 1/120. The eosinophils had been preineubated for 1 h either in control medium or 
in one of the 24 h MCS described above, and were added to the assay, without washing, at an effector to 
target ratio of 1,000:1. Killing in the presence of antibody alone was 0 + 0. 
U  Mean ±  1 SD, three replicate tubes. 
When the mononuclear cells were fractionated by adherence to plastic, the adherent 
cells produced significant enhancing activity. To test for the possible involvement of 
an  adherent  lymphocyte,  a  monoclonal  antilymphocyte  antibody  was  used  to  kill 
both T  and B lymphocytes. The remaining cells still produced the enhancing activity. 
Thus,  although  eosinophilia  and  eosinopoiesis  are  associated  with  T  lymphocyte 
involvement, the enhancing activity we have described here appears to be produced 
by an  adherent,  macrophagelike cell. This  is not  surprising, since macrophages  are 
known to produce various biologically active mediators, including colony-stimulating 
factors (23), interleukin I  (a 13-16,000 tool wt protein which leads to the proliferation 
and activation of T  lymphocytes)  (24), interferon, fibroblast-activating factor (a 40- 
60,000 mol wt protein inducing proliferation of fibroblasts) (25), prostaglandins, and 
various complement components  (26). 
Several properties of the MCIS have been investigated. The enhancing activity was 
relatively heat stable (50% loss after heating at  100°C  for 30 min), with a  molecular 
weight of approximately 35-45,000. ESP is also relatively heat stable with a molecular 
weight  range of 24-56,000  (27,  28),  but  is produced by sensitized T  cells only upon 
exposure to the specific antigen or mitogen. The activity of ESP is lost at dilutions of 
1/4  to  1/8, whereas  the enhancing activity described here is more comparable with 
CSF-t~, being effective at dilutions up to  1/400.  The MCS activity is also distinguish- 
able from  eosinophilopoietin, found  in  the  serum  of eosinophil-depleted mice  (29), 
and from the mast cell-derived ECF-A, both being peptides of low molecular weight. 
Enhancing activity was produced early, being detectable in MCS after 1 h  of culture, 
and required protein synthesis for its production or release. Interleukin I  activity, on 
the other hand, is only detectable after 6 to 12 h of culture, even after induction of the 
cells with lipopolysaccharide (LPS), immune complexes, or lymphokines (24): unstim- 
ulated  macrophages  produce  little,  if any,  activity.  Fibroblast-activating factor  is VEITH  AND BUTFERWORTH  1841 
found in macrophage culture supernatants after 1-4 h of culture but, again, the cells 
required stimulation with LPS (25). 
Although  the  enhancing  activity  failed  to  reveal  any  previously  undetectable 
neutrophil-mediated killing, it would be premature to conclude that it is selective for 
eosinophils, since alternative conditions or other neutrophil functions were not tested. 
The mechanism of increased killing is not yet known. Although the enhancement 
is primarily evident in antibody-dependent killing, and although an increased adher- 
ence of eosinophils to larvae has been noted under such conditions, there appears to 
be little effect on the proportion of eosinophils bearing Fc receptors for IgG (unpub- 
lished observations). We have confirmed the finding that HPCM  increases protein 
synthesis in eosinophils (30) but under the same conditions the enhancing activity in 
MCS fails to do so. 
Possibly the most interesting feature of this study was that, although mononuclear 
cells from most individuals produced detectable enhancing activity when the MCS 
were tested undiluted, the MCS that showed most activity and that titrated out to 
the greatest extent were derived from mononuclear cells from eosinophilic individuals. 
This suggests the possibility that there may be some association between enhanced 
eosinophil activity and eosinophilia. However, a  more extensive investigation to test 
larger numbers of normal and eosinophilic individuals, and to examine whether the 
enhancing activity also shows any selective eosinophil colony-stimulating capacity, is 
required to provide a firmer foundation for future speculation. 
Summary 
Previous studies have shown that eosinophils from eosinophilic individuals differ 
functionally from those of normal individuals. In order to test whether agents that 
might induce eosinophilia could also affect eosinophil function, we have compared 
the capacity of culture supernatants from mononuclear cells of eosinophilic or normal 
individuals to  enhance  eosinophil  activity, as  reflected by  an  increased  killing of 
schistosomula of Schistosoma rnansoni in  vitro.  An  enhancing activity was  detected, 
which  increased  both  the  antibody-dependent, and  to  some extent  the  antibody- 
independent killing of schistosomula by eosinophils, in the absence of complement. 
Under similar conditions, the supernatants failed to stimulate an otherwise undetect- 
able neutrophil-mediated killing. The activity could be removed from the assay by 
washing, without reversing previous eosinophil stimulation, and was not directly toxic 
to the schistosomula. 
Preliminary characterization of the activity indicated that it was relatively heat- 
stable at 100°C for 30 min, and had an estimated molecular weight of 35,000-45,000 
as judged by G-200 Sephadex fractionation. The activity was produced by a nonlym- 
phocytic, nonspecific esterase-containing adherent mononuclear cell in the absence of 
either Con A or antigenic stimulation. Significant enhancing activity was detectable 
after 1 h of culture and continued for at least 25 h. Protein synthesis was required for 
its production or release. 
Although the activity was detectable in supernatants from both eosinophilic and 
normal  individuals, the  supernatants  that  demonstrated highest  activity and that 
could be titrated out furthest were generally derived from eosinophilic individuals, 
suggesting that there might he some association between eosinophilia and enhanced 
eosinophit function. t842  ENHANCEMENT  OF HUMAN EOSINOPHIL CYTOTOXICITY 
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